The ROS1ders Interview Dr. Ross Camidge (16-May-2019)

On May 16, 2019, ROS1der co-founder Janet Freeman-Daily interviewed ROS1 expert D Ross Camidge, MD, PhD, Director of Thoracic Oncology and the Joyce Zeff Chair in Lung Cancer Research at the University of Colorado in a Zoom Webinar. We discussed questions that have arisen among experienced patients in The ROS1ders regarding diagnosis, treatment, and research for ROS1+ cancers, such as:

    • What treatment options do I have after crizotinib and lorlatinib have failed?
    • If the cancer in my body is stable while on crizotinib, but I develop brain mets, when should I switch targeted therapies instead of staying on crizotinib and treating the brain mets with stereotactic radiation?
    • Why does the effectiveness of targeted therapies lessen with each subsequent line of treatment?

Thanks to David LeDuc and Dr. Amy Moore of the GO2 Foundation for Lung Cancer for their assistance with the webinar.


Published by

Gray Connections

I was diagnosed with non-small cell lung cancer in May 2011. The cancer became metastatic in October 2011. No, I never smoked anything (except a salmon). I've had no evidence of disease since January 2013 thanks to precision medicine, clinical trials, and other patients. ANYONE can get lung cancer. Using my engineering degrees (MIT SBME 1978, Caltech Aeronautics MS 1984 and ENGR 1986), I enjoyed a 20-year career in aerospace systems engineering as a technical translator of sorts: I researched a scientific or engineering subject and helped others understand how this new gizmo could benefit them. In the time I have left, I want to use my skills to help others who have lung cancer, and increase the visibility and knowledge of lung cancer among those who don't. I also study brain research, enjoy traveling, write science fiction, and geek out about all sorts of science stuff.